Parents wary of HPV vaccination requirements, study finds

Despite a renewed push by health officials to promote HPV vaccination, a new poll finds that only a minority of parents believe laws requiring the vaccines “are a good idea." Others said they were worried the vaccines can cause serious side effects or that they’re a ploy for pharma sales.

According to the research, 21% of parents said they support laws mandating HPV vaccination as a school-entry requirement, but that number jumped to 57% if the laws were to include “opt-out” provisions. Pharmas Merck ($MRK) and GlaxoSmithKline ($GSK) manufacture the shots and for years have battled barriers in growing uptake such as a sex stigma, safety concerns, misinformation and a reluctance by doctors to strongly encourage the vaccines.

Additionally, researchers found that 23% of the parents questioned vaccine safety and 32% said HPV shots are a sales ploy by pharma companies, ABC News reports.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The group conducted the work in response to a growing number of states considering such requirements; Rhode Island, Virginia and Washington, D.C., currently require the vaccines for schoolchildren, according to ABC.

The new numbers add context to an ongoing push to promote HPV vaccination by pharmas and organizations including the National Cancer Institute and the American Society of Clinical Oncologists. In February, all 69 of the NCI’s Cancer Centers joined together and urged more vaccination, calling the vaccines “tragically underused.”

While a HHS 2020 initiative has set HPV vaccination goals for both boys and girls at 80%, 2015 CDC numbers show that only 40% of girls and 21% of boys have received the HPV vaccination.

Earlier this summer, Merck rolled out a new TV ad for its blockbuster vaccine Gardasil featuring images of a young man with cancer questioning whether his parents knew of a vaccine that could have protected him.

Gardasil generated $1.9 billion in sales last year for Merck, far outgunning GlaxoSmithKline’s $128 million tally for Cervarix, but both pale in comparison to early analyst estimates of $4 billion all the way up to $10 billion for the class.

- here’s the study
- more from ABC News

Related Articles:
Merck holds parents accountable in new Gardasil ad campaign
Merck's Gardasil leads to major HPV declines, but coverage holes remain: Study
HPV rates dive following vaccine introduction, national study says
Journal walks back 'seriously flawed' anti-Gardasil study
NCI's Cancer Centers join in HPV vaccination push


Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.